What Genomes2People does

Genomes2People (G2P) is an academic translational genomics research program based at Brigham and Women's Hospital and Harvard Medical School in Boston, founded in 2011. It conducts clinical trials and implementation research aimed at accelerating the clinical adoption of genomic medicine and precision health. Core research areas include whole genome sequencing in newborns (BabySeq Project), the nation's first genomic newborn screening initiative integrated into state public health systems (BEACONS), polygenic risk scoring for six common diseases (GenoVA Study), pharmacogenomic testing for medication optimization, and the development of frameworks for returning actionable genomic results to research participants (PopSeq, PeopleSeq, MVP-ROAR). The program operates a Veteran-focused sub-program, Genomes2Veterans (G2V), at VA Boston Healthcare System, and a joint Precision Population Health initiative with Ariadne Labs targeting primary-care adoption.

G2P is not a commercial entity. It sells no products or services; all activities are funded through research grants from the NIH (including the Common Fund Venture Program), the VA Office of Research and Development, and industry partnerships (notably GeneDx and Illumina for BEACONS, and Sanford Health for the Imagenetics METRICS study). As of 2025, the most significant capital infusion is the $27 million BEACONS award, which will pilot whole genome sequencing in existing state newborn screening infrastructure across seven states with a target of 30,000 newborns over three years. The program maintains a 11-50 person team and disseminates findings through peer-reviewed publications, scientific conferences, and a quarterly newsletter.

Its go-to-market is relationship-driven and institutional rather than commercial: research collaborations with academic medical centers, state public health laboratories, healthcare systems, and federal agencies. Customer segments are research participants (newborns and adults enrolled in studies), the VA healthcare system, and healthcare providers/systems integrating genomic medicine into clinical workflows. The organization's competitive advantages are rooted in talent (Harvard/BWH leadership), accumulated research data assets, regulatory access (NIH, VA, state labs), and a first-mover position in genomic newborn screening.

Name

Genomes2People

Legal name

Genomes2People

Website

https://genomes2people.org

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Genomes2People is a translational genomics research program at Brigham and Women's Hospital and Harvard Medical School that designs and runs clinical trials to accelerate implementation of genomic medicine, including newborn genomic screening, polygenic risk scoring, and pharmacogenomics, funded primarily by NIH, VA, and industry grants.

Ownership category

akta.pro rank

Product category

Genomic Medicine Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Population Genomics & Preventive Precision Health Programs (HLAAANAL), Newborn Screening & Genetic Public Health Laboratories (HLAJAIAJ), Genetic & Prenatal Testing Laboratories (HLAFAMAH)

Keywords

• Genomic medicine research
• Newborn genomic screening
• Translational genomics studies
• Precision health research
• Polygenic risk scoring

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Distribution channels1 record

Marketing channels5 records

Core offering

Genomes2People conducts translational genomics research to accelerate the implementation of genomic medicine, operating large-scale clinical studies in whole genome sequencing for newborns (BabySeq, BEACONS), polygenic risk scoring (GenoVA), pharmacogenomic testing, and return of actionable genomic results to participants. The program is embedded in Brigham and Women's Hospital and Harvard Medical School and is funded through NIH and VA research grants, industry partnerships, and philanthropic donations. It does not sell commercial products or services; its outputs are peer-reviewed evidence, clinical implementation frameworks, and policy-relevant findings that inform precision health adoption.

Product overview

Genomes2People is a research program focused on translational genomics and health outcomes, not a product company. It does not offer commercial products or services for sale. The organization conducts collaborative research initiatives including: BabySeq Project (newborn genome sequencing), PopSeq Project (population genomic sequencing), PeopleSeq Consortium (returning genomic results to healthy individuals), BEACONS (genomic newborn screening initiative), MedSeq Project (genome sequencing in medicine), Genomes2Veterans/G2V (Veterans genomic medicine), and various working groups focused on economics, life insurance, and precision population health. These are research studies and programs, not commercial products.

Differentiator

Problem solved

Functional benefit

Brands

• Genomes2Veterans: Research program at Veterans Affairs Boston Healthcare System focused on bringing genomic medicine to Veterans
• BabySeq Project
• BEACONS

Products and services

• BEACONS (Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening) National genomic newborn screening research initiative that integrates whole genome sequencing into existing state public health newborn screening systems using the blood spot collected at birth. Designed for state public health laboratories and healthcare systems participating in translational research on newborn sequencing feasibility and outcomes.
• BabySeq Project Whole genome sequencing research project screening newborns for genetic childhood disease risk and examining pediatricians' incorporation of genetic information into newborns' medical care. BabySeq2 focuses on a diverse cohort representative of the general population to assess risks and benefits of newborn genome sequencing for everyday care.
• PopSeq Project Population genomics research project that returns genomic results (gRoR) in an all African American population cohort and a primarily European American cohort, studying gRoR outcomes and comparing results between cohorts to inform population cohort studies and biobanks planning to return genomic results.
• PeopleSeq Consortium Consortium studying the consequences of receiving personal genomic sequencing results in healthy individuals, contributing evidence on the behavioral, clinical, and economic outcomes of personal genomics.
• MedSeq Project Project exploring the use of genome sequencing in clinical medicine, generating evidence on the integration of genomic information into adult medical care.
• Genomes2Veterans (G2V) Research Program VA-based research program bringing genomic medicine to Veterans, including projects such as ProGRESS, ScreenShare Study, MVP-ROAR, and I-PICC Study funded by the VA Office of Research and Development.
• REVEAL Study Research study on the disclosure of genetic risk information for Alzheimer's disease (Apolipoprotein E genotyping) to individuals and their families.
• REVEAL-SCAN Project Extension of the REVEAL Study examining genetic risk disclosure in additional populations and contexts.
• MilSeq Project Project studying genomic sequencing in military service members and related translational genomics questions.
• PGen Study Study examining the implementation and outcomes of personal genomic testing in clinical settings.
• GenoVA Study Pragmatic randomized controlled trial of polygenic risk scoring in primary care, evaluating clinical utility and outcomes for common diseases.
• Precision Population Health Joint initiative with Ariadne Labs combining genomic research expertise with implementation science to overcome barriers to precision medicine adoption in primary care.
• Econogenomics Working Group Working group focused on the economic analysis and health economics of genomic medicine implementation.
• Genomics and Life Insurance Working Group Working group studying the ethical, legal, and social implications of genomic information for life insurance and related policy questions.
• Sanford Imagenetics METRICS Study Study funded by Sanford Health that evaluates outcomes of the Sanford Chip genetic testing program in primary care settings.

Segments3 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and secondary.

• Brigham and Women's HospitalcoreStrategic or Co-development PartnerG2P is based at Brigham and Women's Hospital, one of the leading academic medical centers in the US. The hospital provides institutional infrastructure and clinical research capabilities.
• Harvard Medical SchoolcoreStrategic or Co-development PartnerG2P Director Robert C. Green is Professor of Medicine at Harvard Medical School. The partnership provides academic credibility and research collaboration opportunities.
• Veterans Affairs (VA) Boston Healthcare SystemcoreStrategic or Co-development PartnerG2V Research Program is based at VA Boston Healthcare System, focusing on genomic medicine implementation for Veterans. Provides access to Veteran population for clinical research.
• Ariadne LabscoreStrategic or Co-development PartnerJoint initiative on Precision Population Health combining G2P's genomic research expertise with Ariadne Labs' implementation science capabilities to overcome barriers to precision medicine adoption in primary care.
• Broad InstitutecoreStrategic or Co-development PartnerCollaboration with Broad Institute of MIT and Harvard for genomic research capabilities and sequencing technology.
• Mass General BrighamcoreStrategic or Co-development PartnerG2P is affiliated with Mass General Brigham healthcare system, enabling clinical research integration and implementation studies.
• State Public Health LaboratoriescoreStrategic or Co-development PartnerBEACONS project partners with seven state newborn screening programs to integrate whole genome sequencing into existing public health newborn screening infrastructure.
• Sanford HealthsecondaryStrategic or Co-development PartnerSanford Imagenetics METRICS Study funded by Sanford Health evaluates outcomes of the Sanford Chip genetic testing program in primary care settings.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• HudsonAlpha Institute for Biotechnology: HudsonAlpha is a genomics research institute conducting clinical sequencing, newborn screening research, and population genomics studies. Directly comparable to G2P's translational genomics and newborn screening research focus.
• Baylor College of Medicine Human Genome Sequencing Center: Baylor HGSC operates large-scale clinical sequencing programs and newborn screening research. Comparable to G2P's translational genomics research infrastructure and clinical sequencing capabilities.
• deCODE genetics (Amgen): deCODE genetics runs population-scale genomic studies in Iceland with return of results and polygenic risk research. Strongly comparable to G2P's GenoVA polygenic risk scoring and population genomics evidence-generation work.
• Geisinger MyCode Community Health Initiative: Geisinger MyCode is one of the largest US population genomics programs returning actionable results to participants embedded in a health system. It is directly comparable to G2P's mission of integrating genomic medicine into routine care and generating evidence for clinical utility.
• Genomics England (100,000 Genomes Project): Genomics England runs a national initiative integrating whole genome sequencing into clinical care and returning results to participants. It mirrors G2P's BEACONS-style mission of demonstrating feasibility and clinical utility of population-scale genomic sequencing.
• Mayo Clinic Center for Individualized Medicine: Mayo Clinic's CIM runs translational genomic medicine programs including population screening and return of results research. Directly comparable to G2P's BabySeq, BEACONS, and G2V implementation research.
• Mount Sinai Million Health Discoveries Program: Mount Sinai's Million Health Discoveries is an academic biobank and genomic medicine initiative returning actionable results to patients. Comparable to G2P's research on returning genomic results in diverse patient cohorts.

Emerging players

• Helix: Helix runs a population genomics platform powering health-system genomic programs and large-scale research cohorts. Comparable to G2P for genomic medicine implementation infrastructure, though operating commercially rather than as an academic research program.
• Color Health: Color Health operates a population genomics platform delivering genetic testing at scale to health systems, employers, and public health programs. It is comparable as a translational genomics player, though commercially oriented versus G2P's research-driven model.

Broad incumbents

• NIH All of Us Research Program: All of Us is a federally funded US population genomics effort enrolling over one million participants and returning genomic results. It overlaps with G2P's translational genomics evidence-generation work but operates at much broader federal scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/genomes2people
• LinkedInlinkedin.com/company/genomes2people

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomes2People